Protocol Ledger

NCT04660760 · Phase II · ACTIVE NOT RECRUITING

Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer

Interventional Phase II clinical trial protocol NCT04660760 sponsored by Academic and Community Cancer Research United in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-06-16 Enrollment: 34 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04660760
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)34 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04660760
Protocol FieldVerified Registry Value
NCT IdentifierNCT04660760
Consolidated Lead SponsorAcademic and Community Cancer Research United
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment34 participants (ACTUAL)
Registered Start Date2021-06-16
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI